GlassScriptPhysician profile
Delano R Small
NPI 1437132917
$9,169.77
in general payments reported to CMS, 2019-2025
35 companies · $723 in 2025
The $723 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,537 · 2020: $1,119 · 2021: $576 · 2022: $1,735 · 2023: $1,427 · 2024: $1,053 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,203.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,722.39 | 2019-2025 | Amplatzer Amulet, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $631.95 | 2019-2025 | Lifevest |
| Inari Medical, INC. | $549.06 | 2021-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Edwards Lifesciences Corporation | $518.52 | 2019-2024 | Sapien 3 Ultra Resilia |
| Amgen INC. | $447.55 | 2019-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $420.57 | 2019 | |
| Philips North America LLC | $406.96 | 2019-2025 | Eagle Eye |
| Novartis Pharmaceuticals Corporation | $372.89 | 2019-2025 | |
| Boston Scientific Corporation | $352.70 | 2019-2023 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.62 | 2019-2025 | Jardiance |
| Pfizer INC. | $251.99 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $186.73 | 2019-2023 | Xarelto |
| Getinge USA Sales, LLC | $168.82 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $156.39 | 2019 | |
| Impulse Dynamics (USA) INC. | $153.07 | 2023-2024 | Optimizer, Optimizer |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $151.61 | 2019-2025 | Eliquis, Camzyos |
| Genzyme Corporation | $149.99 | 2022 | |
| Medtronic, INC. | $139.45 | 2021-2023 | In.Pact Admiral |
| Penumbra, INC. | $134.43 | 2022 | |
| Chiesi USA, INC. | $123.40 | 2020 | |
| Biosense Webster, INC. | $103.85 | 2022 | |
| Abiomed | $100.00 | 2023 | Impella |
| Siemens Medical Solutions USA, INC. | $98.17 | 2019-2020 | |
| Gilead Sciences, INC. | $91.75 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $81.83 | 2023-2024 | Wainua, Andexxa, Farxiga |
| Regeneron Healthcare Solutions, INC. | $62.78 | 2019 | |
| Merck Sharp & Dohme LLC | $42.27 | 2025 | Verquvo |
| Astellas Pharma US INC | $37.15 | 2019 | |
| Novo Nordisk INC | $34.11 | 2025 | Wegovy |
| Amarin Pharma, INC. | $27.58 | 2019 | |
| Angiodynamics, INC. | $25.71 | 2024 | Auryon Laser System 100-120 Vac |
| Bayer Healthcare Pharmaceuticals INC. | $24.64 | 2025 | |
| Csl Behring | $23.73 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $19.93 | 2024 | Arcalyst |
| Heartflow, INC. | $14.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delano Small listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.